NYMC Faculty Publications
An Overview of the Currently Available and Emerging Long-Acting Formulations of Risperidone for Schizophrenia and Bipolar Disorder
Author Type(s)
Faculty
DOI
10.1080/14737175.2024.2370349
Journal Title
Expert Review of Neurotherapeutics
First Page
761
Last Page
771
Document Type
Article
Publication Date
8-1-2024
Department
Psychiatry and Behavioral Sciences
Abstract
INTRODUCTION: Long-acting injectable (LAI) antipsychotic medications can help improve treatment adherence in patients with schizophrenia and bipolar disorder. Despite this, they are underutilized. In 2003, intramuscular risperidone became the first available LAI atypical antipsychotic medication, and since then, a number of competing long-acting risperidone formulations have been brought to market, with additional options under active development. These include intramuscular, subcutaneous, long-acting oral, and implantable formulations. AREAS COVERED: This review summarizes currently available and emerging long-acting risperidone formulations, including efficacy and safety data, and practical considerations aimed to help prescribers distinguish one formulation from another. EXPERT OPINION: There is an expanding number of currently available LAI antipsychotic medications giving patients and providers an opportunity to personalize and individualize care. Rates of adherence to treatment in patients with schizophrenia and bipolar disorder are low, and individualizing care can help improve this. The risperidone LAI treatment landscape includes five options approved by the U.S. Food and Drug Administration, with others under clinical development. These options differ in regard to mode of administration, approved indications, available dose strengths, injection intervals, needle size, injection volume, storage, and other variables. Prescribers should be familiar with these differing options to help patients find the best fit for their individual needs.
Recommended Citation
Faden, J., Ramirez, C., Martinez, V., & Citrome, L. (2024). An Overview of the Currently Available and Emerging Long-Acting Formulations of Risperidone for Schizophrenia and Bipolar Disorder. Expert Review of Neurotherapeutics, 24 (8), 761-771. https://doi.org/10.1080/14737175.2024.2370349